NANOVIRICIDES, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
NANOVIRICIDES, INC. (NNVC) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2017-09-28
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-03-31 was 0.00 shares.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-12-31 was 0.00 shares.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-09-30 was 0.00 shares.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 2.67M shares.
- NANOVIRICIDES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 0.00 shares, a 100.00% decline from fiscal 2013.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2017-06-30 | 0.00 shares 10-K · filed 2017-09-28 | |||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | 0.00 shares 10-Q · filed 2017-05-15 | ||
| 2016-12-31 | 0.00 shares 10-Q · filed 2017-02-14 | 0.00 shares 10-Q · filed 2017-02-14 | ||
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 0.00 shares 10-K · filed 2017-09-28 | |||
| 2016-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | 0.00 shares 10-Q · filed 2017-05-15 | ||
| 2015-12-31 | 0.00 shares 10-Q · filed 2017-02-14 | 0.00 shares 10-Q · filed 2017-02-14 | ||
| 2015-09-30 | 0.00 shares 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | 2.67M shares 10-K · filed 2017-09-28 | |||
| 2015-03-31 | 2.67M shares 10-Q · filed 2016-05-10 | 2.67M shares 10-Q · filed 2016-05-10 | ||
| 2014-12-31 | 2.67M shares 10-Q · filed 2016-02-09 | 2.67M shares 10-Q · filed 2016-02-09 | ||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | 0.00 shares 10-K · filed 2016-09-16 | |||
| 2014-03-31 | 1.71M shares 10-Q · filed 2015-05-15 | 0.00 shares 10-Q · filed 2015-05-15 | ||
| 2013-12-31 | 0.00 shares 10-Q · filed 2015-02-25 | 0.00 shares 10-Q · filed 2015-02-25 | ||
| 2013-06-30 | 1.71M shares 10-K · filed 2015-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |